论文部分内容阅读
目的:探讨直肠癌组织β-catenin和β-Trcp的表达及其临床意义。方法:应用免疫组织化学SP法检测直肠癌组织(60例)、直肠腺瘤组织(42例)和正常直肠黏膜组织(20例)中β-catenin和β-Trcp的表达情况。结果:直肠癌、直肠腺瘤和正常直肠黏膜组织中β-catenin的异位表达率分别为85.0%(51/60)、88.1%(37/42)和5.0%(1/20);膜缺失率分别为65.0%(39/60)、23.8%(10/42)和0(0/20);β-trcp的阳性表达率分别为63.3%(38/60)、57.1%(24/42)和0(0/20)。β-catenin的异位表达、膜表达缺失和β-Trcp的阳性表达与患者的年龄、性别、直肠癌的部位、形态、术前CEA水平、分化程度、Dukes分期和淋巴结转移及远处转移均无明显相关,P>0.05。β-Trcp阳性表达与β-catenin异位表达,在直肠癌组织中呈负相关,P<0.05。在直肠癌和直肠腺瘤组织中分别有18.3%(11/60)和35.7%(15/42)的β-catenin异位高表达同时伴有β-Trcp表达减弱或缺失,分别有58.3%(35/60)和21.4%(9/42)的β-cate-nin膜缺失同时伴有β-Trcp表达减弱或缺失。结论:β-catenin的异位表达和β-Trcp的阳性表达是直肠癌发生发展过程中的早期事件,两者可能成为直肠癌预防及早期诊断的重要标志。
Objective: To investigate the expression of β-catenin and β-Trcp in rectal cancer and its clinical significance. Methods: The expression of β-catenin and β-Trcp in rectal cancer (60 cases), rectal adenoma (42 cases) and normal rectal mucosa (20 cases) were detected by immunohistochemical SP method. Results: The ectopic expression rates of β-catenin in rectal cancer, rectal adenoma and normal rectal mucosa were 85.0% (51/60), 88.1% (37/42) and 5.0% (1/20) respectively. The positive rates of β-trcp were 63.3% (38/60) and 57.1% (24/42) respectively, with the rates of 65.0% (39/60), 23.8% (10/42) and 0 And 0 (0/20). Ectopic expression of β-catenin, loss of membrane expression and positive expression of β-Trcp were associated with age, sex, location and morphology of rectal cancer, preoperative CEA level, differentiation, Dukes stage, lymph node metastasis and distant metastasis No significant correlation, P> 0.05. β-Trcp positive expression and β-catenin ectopic expression in rectal cancer tissue was negatively correlated, P <0.05. Ectopic overexpression of β-catenin was found in 18.3% (11/60) and 35.7% (15/42) of rectal cancers and rectal adenomas accompanied with a decrease or loss of β-Trcp expression of 58.3% 35/60) and 21.4% (9/42) of the β-cate-nin membrane deletion accompanied by weakened or absent β-Trcp expression. Conclusion: The ectopic expression of β-catenin and the positive expression of β-Trcp are early events in the development and progression of rectal cancer, both of which may be important markers for the prevention and early diagnosis of rectal cancer.